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Abstract
In Caucasians with type 2 diabetes, circulating TNF receptors 1 (TNFR1) and 2 (TNFR2) predict 
end-stage renal disease (ESRD). Here we examined this relationship in a longitudinal cohort study 
of American Indians with type 2 diabetes with measured glomerular filtration rate (mGFR, 
iothalamate) and urinary albumin-to-creatinine ratio. ESRD was defined as dialysis, kidney 
transplant, or death attributed to diabetic kidney disease. Age-gender-adjusted incidence rates and 
incidence rate ratios of ESRD were computed by Mantel-Haenszel stratification. The hazard ratio 
of ESRD was assessed per interquartile range increase in the distribution of each TNFR after 
adjusting for baseline age, gender, mean blood pressure, HbA1c, albumin-to-creatinine ratio, and 
mGFR. Among the 193 participants, 62 developed ESRD and 25 died without ESRD during a 
median follow-up of 9.5 years. The age-gender-adjusted incidence rate ratio of ESRD was higher 
among participants in the highest vs. lowest quartile for TNFR1 (6.6, 95% CI 3.3–13.3) or TNFR2 
(8.8, 95% CI 4.3–18.0). In the fully adjusted model, the risk of ESRD per interquartile range 
increase was 1.6 times (95% CI 1.1–2.2) as high for TNFR1 and 1.7 times (95% CI 1.2–2.3) as 
high for TNFR2. Thus, elevated serum concentrations of TNFR1 or TNFR2 are associated with 
increased risk of ESRD in American Indians with type 2 diabetes after accounting for traditional 
risk factors including albumin-to-creatinine ratio and mGFR
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Inflammatory processes play an important role in the pathophysiology of diabetic kidney 
disease. Inflammatory cells have been observed in kidney tissue biopsies from streptozocin-
treated diabetic rats1 and patients with various degrees of diabetic glomerulosclerosis.2 
Moreover, inflammatory markers, including tumor necrosis factor (TNFα) and its receptors 
TNFR1 and TNFR2, are associated with progression of diabetic kidney disease. TNFα is the 
main ligand for both TNFR1 and TNFR2. Depending on a number of local factors and the 
activation of the two receptors, TNFα induces different and sometimes contrasting effects.3 
These effects have been observed mostly in vitro and may not be specific to a particular 
cause of renal disease. Activated TNFR1 is the primary receptor mediating tissue injury 
through proinflammatory signals and/or cell death, whereas TNFR2 may promote cell 
migration, regeneration and proliferation and regulates TNFR1 induced apoptosis.4 In 
addition, TNFR2 may have a synergistic effect with TNFR1 by ligand passing, a process in 
which TNFR2-bound TNFα increases the local TNFα concentration in the vicinity of 
TNFR1.5 TNFR1 and TNF-related apoptosis-inducing ligand (TRAIL) have been implicated 
in pancreatic β-cell destruction associated with type 1 diabetes;6,7 TRAIL correlates 
positively with body fat and serum LDL cholesterol in elderly subjects,8 and was shown to 
induce insulin resistance.9,10 TRAIL gene deletion in ApoE−/− mice fed a high-fat diet 
resulted in increased systemic inflammation, diabetes, accelerated atherosclerosis,11 
suggesting that TRAIL may play a role in the development of diabetes and its macro- and 
micro-vascular complications.
Circulating levels of TNFRs have recently emerged as very robust and independent 
predictors of the progression of diabetic kidney disease in the Joslin Kidney Study. 12–14 In 
that study, elevated concentrations of circulating TNFR1 and 2 were strongly associated 
with subsequent end-stage renal disease (ESRD) in predominantly Caucasian subjects with 
type 2 diabetes after accounting for several risk factors for kidney disease present at 
baseline, including HbA1c, albuminuria, glomerular filtration rate (GFR), free and bound 
TNFα, markers of endothelial dysfunction and markers of systemic inflammation.13
To evaluate the role of circulating TNFRs in a population at high risk of renal function 
decline, we examined the relationship between serum concentrations of TNFR1 and TNFR2 
and progression to ESRD in American Indians with type 2 diabetes.
RESULTS
The study included 193 subjects with type 2 diabetes, followed for a median of 9.5 years 
(interquartile range 7.1–11.6 years). During follow-up, 62 (32%) of the participants 
developed ESRD and 25 (13%) died from natural causes other than diabetic kidney disease 
without progressing to ESRD. Baseline characteristics of the cohort are summarized in 
Table 1. At baseline, 127 subjects (65.8%) were receiving glucose lowering medicines and 
12 (6.2%) were receiving antihypertensive medicines. 61 participants (32%) had normal 
ACR, 72 (37%) had moderate albuminuria, and 60 (31%) had severe albuminuria; mGFR 
was ≥60 ml/min in 171 participants (89%). The frequency distributions of serum 
concentrations of TNFR1 and TNFR2 at baseline are shown in Figure 1. Median serum 
concentrations of the receptors were 2833 pg/ml and 4835 pg/ml, respectively, and both 
distributions were skewed.
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Serum concentrations of TNFR1 and TNFR2 correlated strongly with each other (r=0.78) 
and moderately with mGFR, cystatin C, ACR, age, MAP, and duration of diabetes; they did 
not correlate significantly with HbA1c, BMI (Table 2). The correlations between the serum 
concentrations of the receptors and ACR are shown in Figure 2 (r=0.37, P<0.001 for 
TNFR1, r=0.42, P<0.001 for TNFR2).
Unadjusted and age-sex-adjusted incidence rates of ESRD are shown in Table 3 by quartiles 
of TNFR1 and TNFR2. Compared with the lowest quartile of TNFR1, the age-sex-adjusted 
incidence rate of ESRD was significantly higher among subjects in the third and fourth 
quartiles of TNFR1 (IRR for third quartile =2.4, 95% CI 1.01–5.7; IRR for fourth quartile 
=6.6, 95% CI 3.3–13.3). The age-sex-adjusted incidence of ESRD was significantly higher 
among subjects in the third and fourth quartiles of TNFR2 versus the lowest quartile (IRR 
for third quartile= 2.8, 95% CI 1.2–6.4; IRR for fourth quartile=8.8, 95% CI 4.3–18.0).
Figure 3 shows the cumulative incidence of ESRD at 10 years of follow-up, when 48 of the 
62 cases of ESRD had occurred, according to the level of albuminuria and TNFRs. The 
highest quartile of each TNFR is compared with the lowest three quartiles combined. 
Among participants with severe albuminuria, the cumulative incidence of ESRD at 10 years 
of follow-up was 96.2% in those in the highest TNFR1 quartile at baseline and 44.6% in 
those in lower TNFR1 quartiles (p<0.001). Similarly, for TNFR2 the cumulative incidence 
of ESRD was 88.7% and 47.3%, respectively (p<0.001). Among participants without severe 
albuminuria, the 10-year cumulative incidence of ESRD was 14.4% and 6.1% in the highest 
and lower TNFR1 quartiles, respectively (p=0.51), and 26.9% and 4.7% in the highest and 
lower TNFR2 quartiles, respectively (p=0.049).
In the Cox regression analysis, 26 participants were censored at the time of death (25 deaths 
due to natural causes and 1 death due to injury of external cause) and 105 were 
administratively censored at the end of follow-up (December 31, 2013). Unadjusted hazard 
ratio for ESRD per interquartile range increase of TNFR1 was 2.5 (95% CI 2.1–3.1) and for 
TNFR2 was 2.5 (95% CI 2.1–3.0). Adjusted for age, sex, HbA1c, MAP, ACR and mGFR, 
the incidence of ESRD was 1.6 times (95% CI 1.1–2.2) as high per interquartile range 
increase in the distribution of TNFR1 and 1.7 times (95% CI 1.2–2.3) as high per 
interquartile range increase in the distribution of TNFR2. The univariate and multivariate 
models are shown in Table 4.
For the Cox regression model that included baseline clinical covariates alone (i.e., age, sex, 
HbA1c, MAP, and ACR), the C-index for predicting ESRD was 0.858. The C-index for 
clinical covariates plus mGFR was 0.880; for clinical covariates plus TNFR1 0.873; and for 
clinical covariates plus TNFR2 0.879; each of these markers significantly increased the C-
index for predicting ESRD (P<0.001). After additional adjustment for mGFR, the C-index 
for predicting ESRD increased from 0.880 to 0.887 for TNFR1 (P=0.006) and to 0.888 for 
TNFR2 (P=0.002, Table 5).
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Circulating TNFR1 and TNFR2 were strongly associated with risk of progression to ESRD 
in American Indians with type 2 diabetes and mostly preserved kidney function. These 
associations were present after accounting for the effects of clinically recognized risk 
factors, including HbA1c, blood pressure, ACR, and mGFR. In Cox regression models 
adjusting for the traditional clinical covariates, the hazard ratio for ESRD increased nearly 2 
times per interquartile range increase in the distribution of TNFR1 or TNFR2. Both 
receptors enhanced the discrimination of the survival models for ESRD beyond that 
achievable by the clinically recognized risk factors when examined using the C-index. These 
findings suggest that either receptor may be used as an early predictor of ESRD.
Our findings confirm the important role of circulating levels of TNFRs as predictors of risk 
of ESRD as previously reported in 410 predominantly Caucasian subjects with type 2 
diabetes participating in the Joslin Kidney Study.13 There were some differences, however, 
between the results obtained in these two studies. First, the 10-year cumulative risk of ESRD 
among participants in the 4th (highest) quartiles of TNFR1 and TNFR2 was higher in Pima 
Indians than in Caucasians with type 2 diabetes and severe albuminuria (96% and 89% in 
Pima Indians and 75% and 73% in Caucasians, respectively). This risk was also different in 
subjects in quartiles 1–3 combined (45% and 47% in Pima Indians and 16% and 20% in 
Caucasians, respectively). Second, in subjects without severe albuminuria, although the 10-
year cumulative risk of ESRD according to quartiles of serum TNFRs was very similar in 
both populations and was higher in the 4th quartile than in quartiles 1–3 combined, at 12-
years follow-up the cumulative risk in the Pima Indians converged for the highest and lower 
quartiles of TNFR1.
The absolute concentrations of circulating TNFRs in the Pima Indians were almost twice as 
high as those in the Joslin Kidney Study participants. Previous studies show that obesity is 
associated with macrophage accumulation and increased TNF mRNA expression in adipose 
tissue15,16 and severely obese individuals (BMI~40kg/m2) have much higher TNFR 
concentrations than those who are lean.17 These observations suggest that a higher degree of 
obesity among the Pima Indians may be responsible for their higher TNFR concentrations, 
although other factors might also be involved. Serum concentrations of TNFRs were not 
correlated with BMI or HbA1c, because these variables were narrowly distributed, with 
most participants having high BMI and high HbA1c. The differences in the distribution of 
circulating TNFRs in Pima Indians and Caucasians indicate that the risk of ESRD is not 
associated with a specific threshold of circulating TNFRs that is consistent across 
populations. Factors unrelated to risk of kidney disease may also influence the 
concentrations of circulating TNFRs, suggesting that population-specific risk assessment 
may be needed to identify subjects at high or low risk of ESRD in type 2 diabetes. Such a 
requirement could diminish the clinical value of these measures as biomarkers of diabetic 
kidney disease.
Circulating TNFR1 and TNFR2 were highly correlated with each other in the present study, 
as in the Joslin Study. Moreover, the associations of both receptors with diabetic kidney 
disease progression were equivalent. Similarities in the generation of the soluble forms of 
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these receptors may explain the tight correlation. It remains to be elucidated whether 
alterations of the soluble form generation may be responsible for increase in TNFRs in 
circulation and whether this increase contributes to kidney injury. The 55-kDa TNFR1 and 
75-kDa TNFR2 are cell membrane bound receptors involved in key aspects of the immune 
response. TNFR1 and TNFR2 are released into the extracellular space via inducible 
cleavage of TNFR ectodomain by ADAM17.18 An additional mechanism of the soluble 
form generation, the constitutive release of TNFR1 within exosome-like vesicles, was 
described by Levine et al. 19 The presence of circulating TNFR1 in the exosomal fraction 
was confirmed in the Joslin Kidney Study subjects with diabetic kidney disease, and the 
presence of TNFR2 in the exosomes and correlation of exosomal TNFRs with their 
respective protein expression in leukocytes was also demonstrated.14,20 Exposure of kidney 
organ culture to TNFRs increases tubular apoptosis,21 and development of fibrosis is 
delayed in TNFR-deficient murine models of tubulointerstitial injury.22 Nevertheless, a 
particular role of TNFRs in diabetic kidney disease has not yet been established, but the 
strong association between circulating TNFRs and risk of ESRD argue for development of a 
diagnostic test to identify subjects at risk of ESRD in diabetes.
Since Hasegawa et al. first demonstrated the role of TNFα pathway in the experimental 
model of diabetic nephropathy,1 a number of reports have pointed to potential involvement 
of the TNFα pathway in diabetic kidney disease.23,24 Experimental studies demonstrated 
that TNFα-mediated mechanisms may result in vasoconstriction leading to GFR decline, in 
the disruption of the glomerular barrier resulting in increased permeability to albumin, and 
in the recruitment of inflammatory cells into the kidney.25 TNFα is assumed to mediate 
these actions via its two TNF receptors; nevertheless most of those experimental studies did 
not investigate in greater detail whether TNFRs mediated actually those biological effects of 
TNFα. In humans, TNFα level is associated with diabetic nephropathy,25,26 but these 
associations are weaker than for TNFRs.12–14
We are uncertain whether TNFRs are associated with progression to ESRD in a non-diabetic 
population. Circulating TNFRs were previously shown to associate with renal function and 
albuminuria in subjects without diabetes, but those studies were mainly cross-sectional or 
focused on more advanced stages of chronic kidney disease.27–30 In addition, TNFR1 and 
TNFR2 were also implicated in the development of specific non-diabetic kidney diseases 
such as kidney allograft rejection, immune-complex mediated glomerulonephritis, lupus 
nephritis, hepatitis C virus-associated glomerulonephritis, obstructive renal injury, and 
ANCA-associated vasculitis.31–36 Whether TNFRs are also implicated in the progression of 
these kidney diseases to ESRD, however, is not known.
Strengths of the study include measurement of GFR to account for differences in baseline 
kidney function. In addition, the study has excellent follow-up and was conducted in a 
population with a high baseline GFR. Indeed, 67 (34.7 %) subjects had hyperfiltration, 
defined by an mGFR ≥154 ml/min, a value two standard deviations above the mean mGFR 
for Pima Indians with normal glucose tolerance. Limitations include the small study size, 
and the arbitrary distribution of circulating TNFRs into quartiles, with the most significant 
differences in risk of ESRD observed between the 4th quartile and quartiles 1–3 combined. 
This dose-response relationship needs to be investigated further to identify the best 
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diagnostic criteria to predict risk of ESRD. The potential impact of TNFα on ESRD was not 
explored in this study due to insufficient serum sample volume for measuring free and total 
TNFα, and the effect of TNFRs on cardiovascular mortality was not evaluated due to the 
small number of cardiovascular deaths in this study population. Moderate associations of 
circulating TNFRs with cardiovascular mortality (but weaker than for progression to ESRD) 
were suggested elsewhere.13,37
In conclusion, elevated serum concentrations of TNFR1 or TNFR2 are associated with an 
increased risk of ESRD in American Indians with type 2 diabetes after accounting for 
traditional risk factors including ACR and GFR. Absolute concentrations of these receptors 
in the serum are substantially higher than in a Caucasian type 2 diabetes population, 
suggesting that population-specific risk assessment may be needed to identify subjects with 
type 2 diabetes who are at high or low risk of ESRD.
MATERIALS AND METHODS
Study participants
Between 1965 and 2007, American Indians from the Gila River Indian Community 
participated in a longitudinal study of diabetes and its complications. Each member of this 
community who was at least 5 years old was invited to have a research examination 
approximately every 2 years. Diabetes was diagnosed by a 2-hour post-load plasma glucose 
concentration ≥200 mg/dl (11.1 mmol/l) at these biennial examinations, or when the 
diagnosis was documented in the medical record. For the present study, we selected 
participants from this longitudinal population-based study who had type 2 diabetes and also 
participated in longitudinal studies of kidney function that included measurements of 
glomerular filtration rate (mGFR) by the urinary clearance of iothalamate.38,39
Laboratory measurements
All urine and serum samples were stored at −80°C until assay. Urinary albumin was 
measured by nephelometric immunoassay, and concentrations below the threshold detected 
by the assay (6.8 mg/l) were set to this value in the analyses. Urinary albumin excretion was 
estimated by computing the urinary albumin-to-creatinine ratio (ACR) in units of mg/g. 
ACR was considered normal if <30 mg/g, moderate if ≥30 mg/g but <300 mg/g, and severe 
if ≥300 mg/g.40
Urinary clearance of non-radioactive iothalamate was estimated by the average of four timed 
urine collections, bracketed by the collection of blood samples, made at 20-min intervals 
after a water load and a 60-minute equilibration period. A high performance liquid 
chromatography system with a sensitive ultraviolet light detector was used to assay 
iothalamate at 236 nm (Instrumentation Shimadzu #6A, www.shimadzu.com).41 Serum 
levels of TNFRs were measured in samples collected from the eligible participants between 
July 1989 and December 2001. Measurements were performed by ELISA in Dr. A. 
Krolewski’s laboratory, Joslin Diabetes Center, Boston, MA, according to the same protocol 
used in the Joslin Kidney Study.13 Intra-assay coefficient of variation (CV) for mGFR was 
1.1%, and for TNFR1 and TNFR2 were <5%; the inter-assay CVs were 2.9%, 16%, and 5%, 
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respectively. Reproducibility of the TNFR assays was assessed by intra-class correlation of 
measurements from 21 duplicate samples blinded to the performance laboratory. The intra-
class correlation for TNFR1 was 0.80 and for TNFR2 was 0.97, reflecting good agreement.
Body mass index (BMI) was defined as weight divided by the square of height (kg/m2). 
Mean arterial pressure was calculated as MAP = 2/3 diastolic arterial pressure + 1/3 systolic 
arterial pressure.
The study was approved by the Institutional Review Board of the National Institute of 
Diabetes and Digestive and Kidney Diseases. Each subject gave informed consent at each 
renal clearance study.
Statistical analyses
Baseline clinical and demographic features are presented as medians (interquartile range). 
Participants were followed from their first examination with TNFR measurement until 
December 31, 2013, onset of ESRD, or death, whichever came first. ESRD was defined as 
initiation of dialysis, kidney transplant, or death from diabetic kidney disease if dialysis or 
transplantation was refused. Cause of kidney disease was determined by review of medical 
records and review of available biopsy findings. The concentrations of TNFR1 and TNFR2 
were divided into quartiles for the incidence-density and Kaplan-Meier analyses, with the 
divisions occurring at the 25th, 50th, and 75th percentiles. The incidence rate of diabetic 
ESRD was computed as the number of new cases of ESRD per 1,000 person-years (pyrs) at 
risk according to these quartiles.42 Age- and sex-adjusted incidence rate ratios (IRR) relative 
to the lowest quartile of each TNFR were computed by an incidence-density adaptation of 
Mantel-Haenszel stratification which stratifies events and person-years in a time-dependent 
fashion according to decades of age. This method is robust to sparse data within strata. 
When the values for age changed during follow-up, person-years for each subject were 
apportioned to the appropriate new strata. Tests for general association were computed by 
the Mantel-Haenszel test43 adapted for person-year denominators44 and for linear 
association by the Mantel extension test.45 The trend test for unadjusted incidence rates 
across quartiles of TNFRs is based on a weighted regression analysis that changes estimates 
across the strata.46 Relationships between baseline characteristics and measures of TNFRs 
were examined by Spearman’s correlations.
Unadjusted cumulative incidence of ESRD as a function of follow-up time, stratified by 
quartiles of TNFR1 and TNFR2 and by the level of ACR, was estimated by the Kaplan-
Meier product-limit method. Differences in cumulative incidence were assessed by the log-
rank test. Cox regression analysis was used to estimate the hazard ratio for development of 
ESRD associated with an interquartile range increase in the distribution of each TNFR after 
adjusting for known risk factors for ESRD, including baseline age, sex, MAP, HbA1c, ACR, 
and mGFR. Additional adjustment of the Cox models for diabetes duration, BMI, anti-
hypertensive treatment, and glucose-lowering treatment did not change the conclusions of 
the study, and these variables were therefore not included in the final model. The models 
assessed the risk of outcome for the difference between the upper 75th and lower 25th 
percentile as unit of change in the continuous distribution of each TNFR. Adequacy of the 
fit of each model to individual observations was assessed by inspection of deviance 
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residuals. Product terms of predictor variables did not significantly improve the regression 
models and were not included.
C-indexes and the differences in C-indexes were calculated for each predictive model and 
the 95% CI for the difference in C-indexes was computed based on 1,000 bootstrap samples. 
Hypothesis testing for the difference between C-indexes was performed by likelihood ratio 
tests.47–48 Calculations were performed using SAS software version 9.3 (SAS Institute, 
Cary, NC). All analyses used only baseline measurements because our primary interest was 
the clinically-relevant predictive value of TNFRs at a single time point for subsequent 
development of ESRD.
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Frequency distributions of the baseline serum levels of TNFR1 and TNFR2 in Pima Indians 
with type 2 diabetes.
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Relationships of serum concentrations of TNFR1 and TNFR2 with ACR at baseline on 
logarithmic scales. Spearman’s correlations and their corresponding P-values are shown on 
the figure.
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Cumulative incidence of diabetic end-stage renal disease during 10 years of follow-up, when 
48 of the 62 events occurred, according to quartiles of TNFR1 and TNFR2 at baseline and 
albuminuria status. Cut-points for the 25th, 50th, and 75th percentiles of TNFRs distributions 
are presented in Table 3. Numbers of participants at risk at the end of each 2-year interval 
are indicated along the x-axes. ACR=albumin/creatinine ratio, Qt=quartile, TNFR=tumor 
necrosis factor receptor.
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Table 1
Baseline characteristics of Pima Indians with type 2 diabetes.
Baseline characteristic Median (interquartile range)
n (% male) 193 (29)
Age (years) 46 (39–53)
Diabetes duration (years) 14 (11–19)
BMI (kg/m2) 33 (29–39)
HbA1c (%)* 9.6 (7.7–11.1)
MAP (mmHg) 93 (87–99)
mGFR (ml/min) 133 (100–171)
mGFR (ml/min/1.73 m2) 120 (88–149)
Cystatin C (mg/l) 0.97 (0.87–1.10)
Serum creatinine (μmol/l) 57 (48–74)
ACR (mg/g) 72 (19–493)
TNFR1 (pg/ml) 2833 (2081–4092)
TNFR2 (pg/ml) 4835 (3875–6997)
Glucose-lowering treatment (%) 66
Hypertension treatment (%) 6
*
HbA1c in IFCC units (mmol/mol)=81.4 (60.7–97.8).
TNFR=tumor necrosis factor receptor, mGFR=iothalamate glomerular filtration rate, ACR=urinary albumin-to-creatinine ratio, BMI=body mass 
index, MAP=mean arterial pressure. Cystatin C values are IFCC standardized. Serum creatinine values are IDMS standardized.
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Table 4
Univariate and multivariate adjusted Cox proportional hazard models (HR and 95% CI) for the risk of ESRD 
associated with TNFR1 and TNFR2 in Pima Indians with type 2 diabetes. The unit of change is the difference 
between the 75th and 25th percentiles in the distribution of each TNFR as continuous variable.
Baseline variables Univariate Multivariate
TNFR1 TNFR2
Age (per 5 years) 1.1 (1.0, 1.2) 0.8 (0.7, 0.98) 0.9 (0.7, 0.99)
Sex (females=0, males=1) 1.7 (1.03, 2.9) 1.6 (0.9, 3.0) 1.7 (0.9, 3.1)
MAP (per 5 mmHg) 1.3 (1.2, 1.5) 1.03 (0.9, 1.2) 1.0 (0.9, 1.2)
HbA1c (per 1%) 1.1 (1.004, 1.3) 1.2 (1.03, 1.4) 1.2 (1.04, 1.4)
Log2 (ACR) 1.8 (1.6, 2.0) 1.5 (1.3, 1.7) 1.5 (1.3, 1.7)
Log2 (mGFR) 4.0 (3.0, 5.3) 2.3 (1.5, 3.6) 2.1 (1.4, 3.3)
TNFR1 (per IQR) 2.5 (2.1, 3.1) 1.6 (1.1, 2.2) -
TNFR2 (per IQR) 2.5 (2.1, 3.0) - 1.7 (1.2, 2.3)
HR = hazard ratio, CI= confidence intervals, IQR = interquartile range.
*
ACR and mGFR are expressed as the logarithm base 2 (log2) to reflect the association with ESRD corresponding to a two-fold increase in ACR 
and decrease in mGFR, respectively. Effect measures are expressed as the HRs for an increase per specified unit in the distribution of each 
covariate except for mGFR.
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Table 5
C-indices, differences in C-indices, and P-values for the likelihood ratio tests for the differences in the Cox 
proportional hazards models with and without the biomarker information.
Biomarker
C-index
Difference in C-index (95% CI) Likelihood Ratio P-valueCovariates only* Biomarker + covariates
mGFR 0.858 0.880 0.021 (0.002, 0.055) <0.001
TNFR1 0.858 0.873 0.015 (0.0001, 0.042) <0.001
TNFR2 0.858 0.879 0.021 (0.002, 0.052) <0.001
Covariates+mGFR
TNFR1 0.880 0.887 0.007 (-0.002, 0.022) 0.006
TNFR2 0.880 0.888 0.009 (-0.002, 0.029) 0.002
*
Including age, sex, HbA1c, MAP, and ACR
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